Dataset Information

An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.

ABSTRACT: OBJECTIVE:The aim of this study was to investigate ziprasidone plasma concentration, daily dose and clinical efficacy and safety in Han Chinese and Mongolian patients with first-episode schizophrenia. METHODS:A total of 123 inpatients affected by schizophrenia were recruited from the Mental Health Center of Inner Mongolia in China. Ziprasidone plasma concentration, clinical efficacy and side effects were systematically evaluated at baseline, and at 1, 2, 4, and 6 weeks. Metabolic measures such as changes in weight, body mass index (BMI), fasting blood glucose (FBG), triglycerides, and cholesterol, were also recorded. RESULTS:90 patients completed the study. Compared with Han patients, on average, Mongolian patients received a significantly higher ziprasidone dosage for adequate symptom control during the 6-week period and had a lower plasma concentration-to-dose ratio. The Mongolian patients also experienced greater increases in weight and BMI. No significant differences between the two ethnic groups were found in the rate of reduction in the Positive and Negative Syndrome Scale (PANSS) score, Treatment Emergent Symptom Scale (TESS) total score, FBG, triglycerides, cholesterol or Q-Tc interval. CONCLUSION:Compared to Han Chinese patients, Mongolian patients appeared to have increased ziprasidone clearance and require higher doses to achieve effective treatment for schizophrenia.

SUBMITTER: Lv D

PROVIDER: S-EPMC5440439 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.

Lv Dongsheng D Zhao Meirong M Chen Lixia L Yu Dongsheng D Yun Xiaobin X Yang Qing Q Huang Xiaojun X

Psychiatry investigation 20170516 3

<h4>Objective</h4>The aim of this study was to investigate ziprasidone plasma concentration, daily dose and clinical efficacy and safety in Han Chinese and Mongolian patients with first-episode schizophrenia.<h4>Methods</h4>A total of 123 inpatients affected by schizophrenia were recruited from the Mental Health Center of Inner Mongolia in China. Ziprasidone plasma concentration, clinical efficacy and side effects were systematically evaluated at baseline, and at 1, 2, 4, and 6 weeks. Metabolic ...[more]

PMID: 28539955

Similar Datasets

Project description:Ziprasidone is a newer "atypical" or "second-generation" antipsychotic. Oral ziprasidone (ziprasidone hydrochloride) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psychotic features). Ziprasidone intramuscular (ziprasidone mesylate) is FDA-approved for acute agitation in patients with schizophrenia. Oral ziprasidone appears efficacious, and has been shown to have some limited clinical advantages over chlorpromazine and haloperidol in ameliorating negative symptoms of schizophrenia. In Phase 2 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia, ziprasidone did not match the clinical performance of olanzapine and risperidone, appearing closer in overall effectiveness to quetiapine. The rate of dose titration and the dose achieved may have an important bearing on ziprasidone's efficacy profile. In studies of usage for acute agitation in individuals with schizophrenia, intramuscular ziprasidone has been shown to be efficacious and relatively well tolerated. Regarding tolerability, ziprasidone, has important advantages in that it is not associated with clinically significant weight gain or adverse changes in cholesterol, triglycerides, or glycemic control, and patients may experience moderate improvement in these measures when switching to ziprasidone from a different antipsychotic agent. It also lacks significant persistent effects on prolactin levels, is not anticholinergic, and only infrequently causes extrapyramidal side effects or postural hypotension, although it can be associated with somnolence. This tolerability profile may be quite valuable in the treatment of some patients. Ziprasidone may prolong the electrocardiogram (ECG) QTc interval (QT interval corrected for heart rate by a standard algorithm), but after 5 years' clinical availability ziprasidone (by itself) does not appear to pose a substantial clinical problem in this regard. Therefore, ziprasidone may be considered a first-line drug option in the treatment of schizophrenia or manic episodes, but, in view of the differences among antipsychotic medications, drug selection should be guided by the patient's individual characteristics and situation.

Project description:Africa’s environmental, cultural and genetic diversity can significantlygreatly influences how the populations’ respondse to infectious diseases, including malaria, caused by Plasmodium falciparum. Differences in susceptibility to malaria between populations are documented but the underlying mechanisms are poorly understood. The Fulani ethnic group in Africa was reported to be less susceptible to malaria compared to other sympatric groups, such as the Mossi., They exhibit with lower disease rates and parasite load, as well as higher levels of serological protection. Unraveling the underlying genetic, molecular and cellularimmunological basis of this protection remains challenging, in part due to a lack of in-depth immunological characterization at the cellular level. Therefore, to address this question, we performed single cell transcriptomic RNA sequencing analysis ofon peripheral blood mononuclear cells from 126 infected and non-infected Fulani and Mossi children in rural Burkina Faso., This analysis generateding > 70,000 single-cell RNA-Seq profiles and identifiedying 30 cell subtypes. By performing cell subtype proportion analysis, we report an increased abundance of γδ T cells in infected Fulani samples compared to the Mossi counterpart. Moreover, cell-type specific differential expression analysis revealed ethnic-specific immune signatures in both infection states, and highlighted lower pro-inflammatory responses in the monocytes and T cell subtypes of the Fulani in both infection states, with a stronger activation and inflammatory profile in their B cell subtypes. Single-cell expression quantitative trait loci (eQTL) analysis in monocytes of infected samples revealed several significant regulatory variants with ethnic-specific effects. Overall, the results demonstrate the power of single cell transcriptomics in identifying ethnic, cell-type specific and genetic regulatory effects in the host immune response to malaria and provide valuable single-cell eQTL and transcriptomic data from populations underrepresented in genomic studies.

Dataset Information

An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.

Publications

An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets